Market revenue in 2023 | USD 80.9 million |
Market revenue in 2030 | USD 161.1 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.07% in 2023. Horizon Databook has segmented the Italy head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The healthcare system in Italy is well-established, contributing to growth of the head and neck cancer therapeutics market in the country. Moreover, market growth can be attributed to the local presence of major players and increasing research activities in cancer drug development.
The increased geriatric population in the country, which is prone to developing head and neck cancer, further creates opportunities for market growth. For instance, according to an article published in the International Journal of Environmental Research and Public Health, in Italy, about 24% of the population was aged 65 years or above, which is projected to increase to 30% by 2040.
The increasing incidence of head and neck cancer cases is expected to boost the market in Italy. According to an article published in the European Archives of Oto-Rhino-Laryngology in November 2021, every year, there are about 172,000 new head and neck cancer cases diagnosed in Italy.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Italy head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account